Celularity Inc
CELU3.180USD
+0.060+1.92%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
71.70MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celularity Inc Unternehmen
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Unternehmensinformationen
BörsenkürzelCELU
Name des UnternehmensCelularity Inc
IPO-datumMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Anzahl der mitarbeiter123
WertpapierartOrdinary Share
GeschäftsjahresendeMay 23
Addresse170 Park Ave
StadtFLORHAM PARK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07932
Telefon19087682170
Websitehttps://celularity.com/
BörsenkürzelCELU
IPO-datumMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
Aktionäre
Aktionäre
Anteil
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
Aktionärstypen
Aktionäre
Anteil
Corporation
36.88%
Individual Investor
14.45%
Investment Advisor
9.43%
Insurance Company
3.19%
Investment Advisor/Hedge Fund
1.17%
Hedge Fund
0.35%
Research Firm
0.30%
Bank and Trust
0.20%
Venture Capital
0.04%
Other
33.99%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
104
15.81M
66.01%
-1.35M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Celgene Corporation
1.20M
4.99%
--
--
Feb 07, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Kehler (Dean C)
281.94K
1.18%
--
--
Feb 07, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Datum
Art
Verhältnis
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
